Cancer clinical trials in the region Île-de-France

785 currently recruiting clinical trials
Region Île-de-France
Phase 3 Endometrial cancer #NCT05255653 #2023-503267-42-00
Required histologic sub types
Endometrioid adenocarcinoma Serous adenocarcinoma Clear cell carcinoma Dedifferentiated and undifferentiated endometrial ... Carcinosarcoma Other
Required FIGO stages
Stage I Stage II Stage III
Required disease stage
Localized Locally Advanced
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive Surgery
Excluded genetic anomalies
POLE
Excluded previous treatments at localized stage
Immunotherapy Radiotherapy
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
10 recruiting sites
Centre médical universitaire de Leiden
Phase 3 Prostate cancer #NCT05974774 #2023-506817-23-01
Required disease stage
Metastatic Hormone-sensitive
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Hormone therapy
9 recruiting sites
EORTC - Organisation Européenne pour la Recherche et le Traitement du Cancer
Phase 3 Stomach and esophageal cancer #NCT06901531
Required histologic types
Stomach Oesogastric junction
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
Claudin 18.2
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Required CPS scores
CPS Positive (1 <= X < 5) CPS Positive (5 <= X < 10) CPS Positive (X >= 10)
Excluded genetic anomalies
HER2
17 recruiting sites
Astellas Pharma Développement mondial, Inc.
Phase 3 Bladder / Urinary Tract / Urethral cancer #NCT06960577 #2024-519246-75-01
Required histologic types
Invasive bladder cancer
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy Chemotherapy
17 recruiting sites
AstraZeneca
Phase 3 Myelodysplastic Syndromes (MDS) and Myeloproliferative Neoplasms (MPN) #NCT06499285 #2024-516009-22-00
Required histologic types
Myelodysplastic syndromes (MDS)
Required histologic sub types
MDS de novo
Required number of previous lines of therapy
1
Required previous treatments
EPO / Growth factors
Required medullary blasts
< 5 %
Required transfusion dependency statuses
Transfusion-dependent
Required IPSS-R prognostic scores
Very low Low Intermediate
Excluded genetic anomalies
del(5q)
Excluded previous treatments
Systemic Treatment-Naive Chemotherapy Allogeneic stem cell transplant Erythroid maturation agent
4 recruiting sites
Takeda
Phase 3 Colon cancer Rectal cancer #NCT07549412 #2025-524648-37-00
Required disease stage
Metastatic
Required number of previous lines of therapy for current stage of disease
1 2
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
9 recruiting sites
EMD Serono Research & Development Institute, Inc.
Phase 3 Lung cancer #NCT07431827 #2024-517337-41-00
Required histologic types
NSCLC (Non-Small Cell Lung Cancer)
Required histologic sub types
Non-squamous NSCLC
Required disease stage
Localized
Required genetic anomalies
KRAS G12C
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive Surgery Immunotherapy Chemotherapy
4 recruiting sites
Merck Sharp & Dohme LLC
Phase 3 Multiple myeloma #NCT07665450
Required histologic types
Symptomatic multiple myeloma
Required histologic sub types
Monoclonal component measurable
Required central nervous system lesions
None
Required number of previous lines of therapy
None
Required previous treatments
Systemic Treatment-Naive
9 recruiting sites
Janssen
Phase 3 Breast cancer #NCT05696626 #2023-503708-10-00
Required HER2 statuses
HER2 Negative
Required HR statuses
HR Positive
Required disease stage
Locally Advanced Metastatic
Required genetic anomalies
ESR
Required number of previous lines of therapy for current stage of disease
1 2
Required previous treatments at advanced or metastatic stage
Targeted therapy Hormone therapy
Excluded genetic anomalies
Other mutation
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
13 recruiting sites
Sermonix Pharmaceuticals Inc.
Phase 3 Sarcoma and GIST #NCT07585266 #2025-524934-24-00
Required histologic types
GIST
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GlaxoSmithKline